Does a Negative Vitreous THC Test Exclude Exposure? Evidence From Tissue Distribution Research

A negative result in one tissue cannot automatically exclude cannabinoid exposure throughout the body. In a controlled pig study, THC was not detected in vitreous humor or dura mater even though other tissues demonstrated its distribution. The result illustrates why specimen choice matters.

What the experiment measured

Schaefer and colleagues examined JWH-210, RCS-4, and THC after intravenous administration to pigs, with six animals studied for each drug. Tissue collection at six hours allowed comparison of parent compounds and metabolites across anatomical sites.

This was an animal distribution experiment following a defined intravenous dose. It was not a human autopsy series, a study of typical smoked cannabis use, or a driving experiment. Its concentrations should be interpreted within those conditions.

THC and synthetic cannabinoids differed

The investigators detected THC in multiple tissues, but not in vitreous humor or dura mater under the study’s analytical conditions. The other parent cannabinoids did not show that same absence in those specimens. Brain concentrations were moderate rather than making the brain a universally dominant reservoir.

Elimination-related tissues contained substantial metabolites, and the investigators identified bile as potentially useful for documenting cannabinoid exposure. A metabolite-rich specimen answers a different question from measuring parent THC in blood.

What a nondetection actually says

Nondetection means that the target was not measured above the method’s detection capability in that specimen. It is not proof that the animal received no THC. In this experiment, administration was independently known.

Conversely, detecting a compound in a tissue does not establish functional impairment at an earlier time. Tissue distribution, circulating concentrations, and behavior are distinct endpoints. This study did not validate a concentration that identifies impairment or explains a human death.

Applying the finding without overstating it

A forensic interpretation should specify the specimen, analyte, detection limit, route, and elapsed time. This study gives a concrete reason to resist treating every negative matrix as interchangeable. It does not establish that human vitreous specimens are always negative after cannabis use, or that a positive bile result determines when consumption occurred.

The intravenous route and limited observation point also prevent a reliable conversion into a smoked dose or a universal human detection window. Distribution evidence is most useful when it narrows an inference to the question actually tested.

For related context, see our discussion of interpreting THC blood concentrations.

Primary research

Nadine Schaefer; Mattias Kettner; Matthias W. Laschke; Julia Schlote; Andreas H. Ewald; Michael D. Menger; Hans H. Maurer; Peter H. Schmidt. Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and ∆ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs. Current Neuropharmacology (2017). DOI: 10.2174/1570159X15666161111114214.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

What Skin Tags Along an Abrasion Can Show About Direction

Knight’s Forensic Pathology explains how superficial skin fragments can help interpret a scraping injury.

Spread the love

Read Article: What Skin Tags Along an Abrasion Can Show About Direction

Why Stomach Contents Provide an Uncertain Timeline After Death

Knight’s Forensic Pathology explains how meal composition and stress complicate estimates based on stomach contents.

Spread the love

Read Article: Why Stomach Contents Provide an Uncertain Timeline After Death

What Did the Confirmatory Phase 3 MDMA-Assisted Therapy Trial Add?

The MAPP2 trial replicated symptom and functional improvements in a more ethnoracially diverse PTSD sample. It also left important questions about blinding, long-term outcomes, exclusions, and sponsor involvement.

Spread the love

Read Article: What Did the Confirmatory Phase 3 MDMA-Assisted Therapy Trial Add?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us